



Manufacturing of Wosulin (recombinant insulin) Injection at Wockhardt Biotech Park, India

INDIA

**Building Power Brands
In-licensing Niche Products**



Wockhardt India business has been consistently recording double digit growth since the past three years, moving ahead of the industry growth and gaining market share. 29 new products were launched during the year. **Furthermore, our range of 'Power Brands' have demonstrated a healthy growth of 22%. Our infant food segment also witnessed a surge above 20%.**

In-Licensed Product	Company	Launch
Vitix	LSI, UK	2007
Viticolor	ACM Crawford, France	2007
Pedistine	Gnosis, Italy	2007
Kelocote	ABT, USA	2007
BioCorneum	ABT, USA	2007
B-Lift Range	Syrio, Italy	2008
Zinderm	Crawford, UK	2008
Novophane	ACM Crawford, France	2008
Mobiwok	Indena, Italy	2008
Sammy	Gnosis, Italy	2008
Normagut	Gnosis, Italy	2008

AGGRESSIVE IN-LICENSING STRATEGY

Wockhardt has finalised 11 in-licensing arrangements with European and American companies in the field of dermatology, derma-cosmetology, oncology, medical nutrition and osteoarthritis meeting the unmet needs of the Indian patients. Already, 5 in-licensed products have been launched in India.

8 BRANDS INTO THE ELITE LIST

Today, 8 of our brands adorn the list of India's Top 300 Pharma Brands, 2 of which are among the top 100.



Sunil Khera, President - Domestic & International (ROW) Business, pointing out market details to his divisional heads

GAINING GROUNDS IN DIABETOLOGY

The growth of our oral diabetology business exceeded 30%. Also, our recombinant insulin injection, Wosulin, has witnessed a good growth.

'LONG ACTING INSULIN' SOON TO GET LAUNCHED

DCGI has approved marketing of Wockhardt's recombinant insulin analogue, Glargine. **Very soon Indian patients will get the benefit of the 'long acting insulin'. Wockhardt is second in the world to have developed this technology driven insulin.**

ANIMAL HEALTH DIVISION GOES GLOBAL

With growth touching every aspect of our India business, our Animal Health Division has also exhibited an impressive performance, with exports accounting for 15% of its revenues.